Skip to main content
Top
Published in: Clinical and Translational Oncology 10/2014

01-10-2014 | Brief Research Article

Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

Authors: A. López-González, C. Salas, M. Provencio, M. Córdoba, C. Gamallo

Published in: Clinical and Translational Oncology | Issue 10/2014

Login to get access

Abstract

Purpose

Aldehyde dehydrogenase enzymes are a family of intracellular enzymes that participate in cellular detoxification, differentiation and drug resistance through the oxidation of cellular aldehydes. The isoform 1 (ALDH1) has been proved useful for the identification of cancer stem cells. The ALDH1 cytoplasmatic expression has been associated with poor prognostis in several tumours, such as non-small cell lung cancer. The role of the ALDH1 nuclear expression remains unknown.

Methods

We conducted a historical cohort study in 89 patients diagnosed of stage I non-small cell lung cancer treated with surgery between 2009 and 2004 in the Thoracic Surgery Department in the Universitary Hospital Puerta de Hierro. We selected from this sample those cases with nuclear expression of the ALDH1.

Results

Three of the 89 (3.3 %) patients showed a nuclear expression of the ALDH1. The three of them are still alive with a median time of follow up of 73 months (more than 6 years).

Conclusion

We have identified ALDH1 as a nuclear protein in early stage non-small cell lung cancer. It might have a function in cell cycle control, associating a better prognosis to these patients. More studies are necessary to clarify the role of nuclear expression of ALDH1.
Literature
1.
go back to reference Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225–33.CrossRef Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225–33.CrossRef
2.
go back to reference Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38:331–6.PubMedCrossRef Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38:331–6.PubMedCrossRef
3.
go back to reference Sullivan J, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor iniaition, progresión, and targeted therapy. Cancer Metastasis Rev. 2010;29:61–72.PubMedCrossRefPubMedCentral Sullivan J, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor iniaition, progresión, and targeted therapy. Cancer Metastasis Rev. 2010;29:61–72.PubMedCrossRefPubMedCentral
4.
go back to reference Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7:330–8.PubMedCrossRef Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7:330–8.PubMedCrossRef
5.
go back to reference Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer item and progenitor cells. Stem Cells Dev. 2009;18(1):17–25.PubMedCrossRef Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer item and progenitor cells. Stem Cells Dev. 2009;18(1):17–25.PubMedCrossRef
6.
go back to reference Yoshida A, Hsu LC, Davé V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 1992;46:239–44.PubMed Yoshida A, Hsu LC, Davé V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 1992;46:239–44.PubMed
7.
go back to reference Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancer are characterized by negative estrógeno receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100:1062–8.PubMedCrossRef Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancer are characterized by negative estrógeno receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100:1062–8.PubMedCrossRef
8.
go back to reference Charape-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1 positive cancer item cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55.CrossRef Charape-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1 positive cancer item cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55.CrossRef
9.
go back to reference Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77:162–7.PubMedCrossRef Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77:162–7.PubMedCrossRef
10.
go back to reference Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, et al. Aldehyde dehydrogenase 1-positive cell population is enriched in tumor-initiating cells and associated with progresión of bladder cancer. Cancer Epidemiol Biomark Prev. 2010;19:327–37.CrossRef Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, et al. Aldehyde dehydrogenase 1-positive cell population is enriched in tumor-initiating cells and associated with progresión of bladder cancer. Cancer Epidemiol Biomark Prev. 2010;19:327–37.CrossRef
11.
go back to reference Stagos D, Chen Y, Cantore M, Jester JV, Vasiliou V. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15:211–8.CrossRef Stagos D, Chen Y, Cantore M, Jester JV, Vasiliou V. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15:211–8.CrossRef
12.
go back to reference Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59(3):340–9.PubMedCrossRef Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59(3):340–9.PubMedCrossRef
13.
go back to reference Stagos D, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15:21–218. Stagos D, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. Corneal aldehyde dehydrogenases: multiple functions and novel nuclear localization. Brain Res Bull. 2010;15:21–218.
14.
go back to reference Pappa A, Brown D, Koutalos Y, DeGregori J, White C, Vasiliou V. Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epitelial cells. J Biol Chem. 2005;280:27998–8006.PubMedCrossRef Pappa A, Brown D, Koutalos Y, DeGregori J, White C, Vasiliou V. Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epitelial cells. J Biol Chem. 2005;280:27998–8006.PubMedCrossRef
Metadata
Title
Aldehyde dehydrogenases in early stage lung cancer: nuclear expression
Authors
A. López-González
C. Salas
M. Provencio
M. Córdoba
C. Gamallo
Publication date
01-10-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1173-y

Other articles of this Issue 10/2014

Clinical and Translational Oncology 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine